Key result
Metabolic syndrome in hypertensive patients is associated with subclinical target organ damage, which increases the risk of fatal and nonfatal cardiovascular events.
Routine screening for target organ damage is recommended in hypertensive patients with metabolic syndrome to optimize initial therapy and monitor treatment efficacy.
Metabolic syndrome organ damage may aid risk stratification; leaves open whether targeting it improves outcomes.
A growing body of evidence indicates that the clustering of metabolic and hemodynamic abnormalities characterizing the metabolic syndrome is associated with a prevalence of subclinical damage in a variety of organs, such as left ventricular hypertrophy, thickening or atherosclerotic plaques of carotid arteries, microalbuminuria and deranged renal function. This is clinically relevant since these markers of target organ damage are associated with an increased risk of cardiovascular fatal and nonfatal events. The contribution of the metabolic syndrome to target organ damage in hypertensives is presumably responsible for a substantial increase in cardiovascular fatal and nonfatal events. Thus, target organ damage should be routinely searched for in hypertensives with metabolic syndrome in order to define initial therapeutic strategies and to monitor treatment-induced protection.
No takes yet. Share an insight, caveat, or question.
Cuspidi et al. (2008) conducted a review in Metabolic syndrome and hypertension. Metabolic syndrome was evaluated on Target organ damage (left ventricular hypertrophy, carotid plaques, microalbuminuria). Metabolic syndrome in hypertensive patients is associated with subclinical target organ damage, which increases the risk of fatal and nonfatal cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: